MEI Pharma Inc. (NASDAQ: MEIP)
$2.90
+0.0600 ( +2.11% ) 14.4K
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Market Data
Open
$2.90
Previous close
$2.84
Volume
14.4K
Market cap
$18.72M
Day range
$2.83 - $2.92
52 week range
$2.73 - $7.87
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jun 25, 2024 |
4 | Insider transactions | 1 | May 21, 2024 |
8-k | 8K-related | 53 | May 21, 2024 |
4 | Insider transactions | 1 | May 20, 2024 |
8-k | 8K-related | 15 | May 09, 2024 |
10-q | Quarterly Reports | 70 | May 09, 2024 |
8-k | 8K-related | 13 | Feb 21, 2024 |
8-k | 8K-related | 14 | Feb 13, 2024 |
10-q | Quarterly Reports | 73 | Feb 13, 2024 |
8-k | 8K-related | 10 | Jan 17, 2024 |